Endothelin-1 activation of JAK2 in vascular smooth muscle cells involves NAD(P)H oxidase-derived reactive oxygen species

Amy K.L. Banes-Berceli, Safia Ogbi, Amany Mohamed Tawfik, Bela Patel, Amanda Shirley, David M. Pollock, David J Fulton, Mario B Marrero

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Endothelin-1 (ET-1) and JAK2 are both implicated in diabetic complications. Therefore, we investigated whether ET-1 differentially actives JAK2 under conditions of normal (5 mM) and high (25 mM) glucose. We tested the hypothesis that reactive oxygen species mediate the activation of JAK2 in response to ET-1. In rat aortic vascular smooth muscle cells (VSMC), ET-1 (10-7 M, 5 min) stimulated the activation of JAK2, which was further enhanced under high glucose conditions. Allopurinol (xanthine oxidase inhibitor, 1 μM) and l-NAME (nitric oxide synthase inhibitor, 1 mM) had no effect on ET-1-induced JAK2 activation, while apocynin (NAD(P)H oxidase inhibitor 100 μM) resulted in a significant inhibition of ET-1-induced JAK2 and MAPK activation. Overexpression of SOD did not inhibit ET-1-induced activation of JAK2, but catalase (50 units/mL) treatment resulted in complete inhibition. In vivo administration of apocynin (1.5 mM) resulted in a significant decrease (∼ 50%), while the ETA receptor antagonist ABT-627 completely inhibited phosphorylation of JAK2 in aortae from STZ-induced diabetic rats. Additionally, DHE staining of aortic sections was significantly reduced in diabetic rats treated with ABT-627. These data suggest that in VSMC, ET-1 via the ETA receptor, utilizes NAD(P)H oxidase to activate JAK2.

Original languageEnglish (US)
Pages (from-to)310-319
Number of pages10
JournalVascular Pharmacology
Volume43
Issue number5
DOIs
StatePublished - Nov 1 2005

Fingerprint

NADPH Oxidase
Endothelin-1
Vascular Smooth Muscle
Smooth Muscle Myocytes
Reactive Oxygen Species
Glucose
Allopurinol
Xanthine Oxidase
Diabetes Complications
Nitric Oxide Synthase
Catalase
Aorta
Phosphorylation
Staining and Labeling

Keywords

  • Diabetes
  • Endothelin-1
  • Reactive oxygen species
  • Vascular smooth muscle cells

ASJC Scopus subject areas

  • Physiology
  • Molecular Medicine
  • Pharmacology

Cite this

Endothelin-1 activation of JAK2 in vascular smooth muscle cells involves NAD(P)H oxidase-derived reactive oxygen species. / Banes-Berceli, Amy K.L.; Ogbi, Safia; Tawfik, Amany Mohamed; Patel, Bela; Shirley, Amanda; Pollock, David M.; Fulton, David J; Marrero, Mario B.

In: Vascular Pharmacology, Vol. 43, No. 5, 01.11.2005, p. 310-319.

Research output: Contribution to journalArticle

Banes-Berceli, Amy K.L. ; Ogbi, Safia ; Tawfik, Amany Mohamed ; Patel, Bela ; Shirley, Amanda ; Pollock, David M. ; Fulton, David J ; Marrero, Mario B. / Endothelin-1 activation of JAK2 in vascular smooth muscle cells involves NAD(P)H oxidase-derived reactive oxygen species. In: Vascular Pharmacology. 2005 ; Vol. 43, No. 5. pp. 310-319.
@article{476f5a81b2a94b3dbe59f0891cb2be36,
title = "Endothelin-1 activation of JAK2 in vascular smooth muscle cells involves NAD(P)H oxidase-derived reactive oxygen species",
abstract = "Endothelin-1 (ET-1) and JAK2 are both implicated in diabetic complications. Therefore, we investigated whether ET-1 differentially actives JAK2 under conditions of normal (5 mM) and high (25 mM) glucose. We tested the hypothesis that reactive oxygen species mediate the activation of JAK2 in response to ET-1. In rat aortic vascular smooth muscle cells (VSMC), ET-1 (10-7 M, 5 min) stimulated the activation of JAK2, which was further enhanced under high glucose conditions. Allopurinol (xanthine oxidase inhibitor, 1 μM) and l-NAME (nitric oxide synthase inhibitor, 1 mM) had no effect on ET-1-induced JAK2 activation, while apocynin (NAD(P)H oxidase inhibitor 100 μM) resulted in a significant inhibition of ET-1-induced JAK2 and MAPK activation. Overexpression of SOD did not inhibit ET-1-induced activation of JAK2, but catalase (50 units/mL) treatment resulted in complete inhibition. In vivo administration of apocynin (1.5 mM) resulted in a significant decrease (∼ 50{\%}), while the ETA receptor antagonist ABT-627 completely inhibited phosphorylation of JAK2 in aortae from STZ-induced diabetic rats. Additionally, DHE staining of aortic sections was significantly reduced in diabetic rats treated with ABT-627. These data suggest that in VSMC, ET-1 via the ETA receptor, utilizes NAD(P)H oxidase to activate JAK2.",
keywords = "Diabetes, Endothelin-1, Reactive oxygen species, Vascular smooth muscle cells",
author = "Banes-Berceli, {Amy K.L.} and Safia Ogbi and Tawfik, {Amany Mohamed} and Bela Patel and Amanda Shirley and Pollock, {David M.} and Fulton, {David J} and Marrero, {Mario B}",
year = "2005",
month = "11",
day = "1",
doi = "10.1016/j.vph.2005.08.024",
language = "English (US)",
volume = "43",
pages = "310--319",
journal = "Vascular Pharmacology",
issn = "1537-1891",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Endothelin-1 activation of JAK2 in vascular smooth muscle cells involves NAD(P)H oxidase-derived reactive oxygen species

AU - Banes-Berceli, Amy K.L.

AU - Ogbi, Safia

AU - Tawfik, Amany Mohamed

AU - Patel, Bela

AU - Shirley, Amanda

AU - Pollock, David M.

AU - Fulton, David J

AU - Marrero, Mario B

PY - 2005/11/1

Y1 - 2005/11/1

N2 - Endothelin-1 (ET-1) and JAK2 are both implicated in diabetic complications. Therefore, we investigated whether ET-1 differentially actives JAK2 under conditions of normal (5 mM) and high (25 mM) glucose. We tested the hypothesis that reactive oxygen species mediate the activation of JAK2 in response to ET-1. In rat aortic vascular smooth muscle cells (VSMC), ET-1 (10-7 M, 5 min) stimulated the activation of JAK2, which was further enhanced under high glucose conditions. Allopurinol (xanthine oxidase inhibitor, 1 μM) and l-NAME (nitric oxide synthase inhibitor, 1 mM) had no effect on ET-1-induced JAK2 activation, while apocynin (NAD(P)H oxidase inhibitor 100 μM) resulted in a significant inhibition of ET-1-induced JAK2 and MAPK activation. Overexpression of SOD did not inhibit ET-1-induced activation of JAK2, but catalase (50 units/mL) treatment resulted in complete inhibition. In vivo administration of apocynin (1.5 mM) resulted in a significant decrease (∼ 50%), while the ETA receptor antagonist ABT-627 completely inhibited phosphorylation of JAK2 in aortae from STZ-induced diabetic rats. Additionally, DHE staining of aortic sections was significantly reduced in diabetic rats treated with ABT-627. These data suggest that in VSMC, ET-1 via the ETA receptor, utilizes NAD(P)H oxidase to activate JAK2.

AB - Endothelin-1 (ET-1) and JAK2 are both implicated in diabetic complications. Therefore, we investigated whether ET-1 differentially actives JAK2 under conditions of normal (5 mM) and high (25 mM) glucose. We tested the hypothesis that reactive oxygen species mediate the activation of JAK2 in response to ET-1. In rat aortic vascular smooth muscle cells (VSMC), ET-1 (10-7 M, 5 min) stimulated the activation of JAK2, which was further enhanced under high glucose conditions. Allopurinol (xanthine oxidase inhibitor, 1 μM) and l-NAME (nitric oxide synthase inhibitor, 1 mM) had no effect on ET-1-induced JAK2 activation, while apocynin (NAD(P)H oxidase inhibitor 100 μM) resulted in a significant inhibition of ET-1-induced JAK2 and MAPK activation. Overexpression of SOD did not inhibit ET-1-induced activation of JAK2, but catalase (50 units/mL) treatment resulted in complete inhibition. In vivo administration of apocynin (1.5 mM) resulted in a significant decrease (∼ 50%), while the ETA receptor antagonist ABT-627 completely inhibited phosphorylation of JAK2 in aortae from STZ-induced diabetic rats. Additionally, DHE staining of aortic sections was significantly reduced in diabetic rats treated with ABT-627. These data suggest that in VSMC, ET-1 via the ETA receptor, utilizes NAD(P)H oxidase to activate JAK2.

KW - Diabetes

KW - Endothelin-1

KW - Reactive oxygen species

KW - Vascular smooth muscle cells

UR - http://www.scopus.com/inward/record.url?scp=27744481080&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27744481080&partnerID=8YFLogxK

U2 - 10.1016/j.vph.2005.08.024

DO - 10.1016/j.vph.2005.08.024

M3 - Article

VL - 43

SP - 310

EP - 319

JO - Vascular Pharmacology

JF - Vascular Pharmacology

SN - 1537-1891

IS - 5

ER -